Sep 2026· British Journal of Clinical Pharmacology· 0 citations· 12 references
Medicine
TL;DR
A coherent clinical taxonomy distinguishing psychoactive, psychotropic, euphorigenic and intoxicant is proposed and the implications of dose, route of administration, patient-level modifiers and statutory definitions for classifying cannabinoids as intoxicants are examined.
Abstract
Aims
This study aimed to clarify the pharmacological meaning of intoxication as it applies to cannabis-based medicines; distinguish intoxication from related terms such as psychoactive, psychotropic and euphorigenic; and evaluate how these distinctions inform clinical practice, prescribing frameworks and regulatory classification of THC- and CBD-containing products.
Methods
A narrative review of pharmacological, clinical and regulatory literature was conducted, drawing on cannabinoid receptor pharmacology, pharmacokinetic studies of THC and CBD, ICD-11 diagnostic criteria for substance intoxication, WHO scheduling assessments and international regulatory frameworks. Evidence was synthesised to develop a coherent clinical taxonomy and to examine the implications of dose, route of administration, patient-level modifiers and statutory definitions for classifying cannabinoids as intoxicants.
Results
THC is a partial CB1 receptor agonist and a dose- and route-dependent intoxicant. Oral administration produces substantially higher exposure to the active metabolite 11-hydroxy-THC, increasing intoxication likelihood and severity. Patient-specific factors further modify intoxication risk. CBD acts as a negative allosteric modulator at CB1, does not produce euphoria or functional impairment at clinically relevant doses and does not meet ICD-11 criteria for an intoxicant. A taxonomy distinguishing psychoactive, psychotropic, euphorigenic and intoxicant is proposed.
Conclusion
THC and CBD differ fundamentally in receptor pharmacology, clinical effects and intoxication potential. Intoxication should be defined by functional impairment, not by psychoactivity alone. Adoption of precise, pharmacologically grounded terminology is essential for rational prescribing, informed consent, patient safety and coherent regulatory policy.
Objective: To review the pharmacological, clinical, and regulatory principles governing the medical use of cannabinoids in Brazil, with emphasis on pharmaceutical-grade products currently authorized for sale in Brazilian pharmacies. Methods: This narrative review synthesized literature published between 2015 and 2025...
Pedro d'Elia Machado Silva, M. D. Martins de Souza, Cassiano Teixeira· Revista de Geopolítica· 0 citations
A greater international regulatory harmonization, stronger quality assurance frameworks, and evidence-based monitoring systems are required for cannabinoids and cannabis products, crucial for protecting public health, supporting scientific research, and enabling the responsible integration of cannabinoid-based therapie...
Shalini Dwivedi, J. G. Vargas, S. Lal· Current Reviews in Clinical...· 0 citations
Cannabis, an ancient plant that has been used for millennia, is increasingly utilized by patients with cancer to alleviate symptoms related to both the disease and its treatment. This complex botanical contains multiple bioactive compounds, most notably delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which in...
D. Behl, Donald I. Abrams, Dylan M. Zylla et al.· Frontiers in Oncology· 0 citations
Cannabis, also called Cannabis sativa, is widely used both recreationally and medicinally for pain relief, gastrointestinal issues, mental health conditions, and seizures. However, despite its medical uses, it is often abused for its psychoactive effects. Its primary active compounds, delta-9-tetrahydrocannabinol (THC)...
Fernand Catherine Ferdinica, Rengasamy Rishikesh, B. Sivamaruthi et al.· Nature Cell and Science· 0 citations